

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Bethesda, MD 20892.

*Contact Person:* Anita Miller Sostek, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4100, MSC 7184, Bethesda, MD 20892, 301-435-1260, [sosteka@csr.nih.gov](mailto:sosteka@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, ZRG1 BECM 40 P: Program Project.

*Date:* March 19-21, 2003.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Melrose Hotel, 2430 Pennsylvania Ave., NW., Washington, DC 20037.

*Contact Person:* Noni Byrnes, PhD., Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4196, MSC 7806, Bethesda, MD 20892, 301-435-1217, [byrnesn@csr.nih.gov](mailto:byrnesn@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Bioengineering Research Partnerships: Genetics.

*Date:* March 19, 2003.

*Time:* 9 a.m. to 11 a.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Michael R. Schaefer, PhD, Scientific Review Administrator, Genetic Sciences IRG, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6166, MSC 7890, Bethesda, MD 20892, (301) 435-2477, [schaeferm@csr.nih.gov](mailto:schaeferm@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Biology of Trypanosomes.

*Date:* March 19, 2003.

*Time:* 1 p.m. to 3 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Wilco Building, 6000 Executive Boulevard, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Robert Freund, PhD., Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4198, MSC 7808, Bethesda, MD 20892, 301-435-1050, [freundr@csr.nih.gov](mailto:freundr@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Bacterial Genomics.

*Date:* March 19, 2003.

*Time:* 1 p.m. to 3 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Jean Hickman, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4198,

MSC 7808, Bethesda, MD 20892, 301-435-1146.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Pediatric Oncology Database.

*Date:* March 19, 2003.

*Time:* 1:30 p.m. to 2:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Elaine Sierra-Rivera, PhD, Scientific Review Administrator, Center for Scientific Review, National Institute of Health, 6701 Rockledge Drive, Room 6184, MSC 7804, Bethesda, MD 20892, 301-435-1779, [riverase@csr.nih.gov](mailto:riverase@csr.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93-306, Comparative Medicine, 93.306; 93.333, Clinical Research, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: February 25, 2003.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 03-5226 Filed 3-5-03; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Statement of Organization, Functions, and Delegations of Authority

Part N, National Institutes of Health, of the Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services (40 FR 22859, May 27, 1975, as amended most recently at 67 FR 54441, August 22, 2002, and redesignated from Part HN as Part N at 60 FR 56606, November 9, 1995), is amended as set forth below to reflect the transfer of the budget function from the Office of the Director, NIH, to the Office of Management, Office of the Director, NIH.

Section N-B, Organization and Functions, under the heading Office of the Director (NA, formerly HNA) is amended as follows:

(1) Immediately following the statement for the Office of Science Policy (NA6, formerly HNA6), the title and functional statement of the Office of Budget (NA7, formerly HNA7) are deleted in their entirety.

(2) Under the heading Office of Management (NAM, formerly HNAM), insert the following:

*Office of Budget (NAM8, formerly HNAM8).* (1) Exercises primary responsibility for NIH-wide budget policy, including planning, analysis,

formulation, and presentation; (2) administers and coordinates budget management after appropriations have been made, including reprogramming and coordination of the use of the Director's Discretionary Fund and transfer authority; and (3) provides budget advice to the Director, NIH, and senior OD and Institute and Center (IC) officials.

*Budget Analysis and Modeling Staff (NAM8-2, formerly HNAM8-2).* (1) Performs modeling of grant and other budget data for projecting major resources as part of the NIH budget development and formulation process; (2) conducts budget analysis and designs and presents a variety of electronically generated tables and visuals to support budget submissions to HHS, OMB, and Congress; (3) completes special analysis projects for the NIH Director; (4) plans, develops, and evaluates budget automation and provides recommendations on the selection and/or design of software that provides trend analyses; and (5) manages the Office of Budget Web page.

*Budget Formulation, Presentation, and Execution Branch (NAM82, formerly HNAM82).* (1) Provides guidance to and coordinates with ICs on budget policy, planning, formulation, justification, and execution of appropriated and nonappropriated funds; (2) serves as the focal point at NIH for the interpretation, preparation, dissemination, and implementation of HHS, OMB, and congressional financial policies and procedures; (3) advises NIH organizations on the preparation, receipt, and review of budgetary data required for formulation and presentation of the budget; (4) administers all assessments of ICs from appropriated funds; (5) coordinates and consolidates NIH budget execution, administration, and financial reporting, which includes development of apportionments, allotments, allowances, reprogramming, transfers, reserves, and similar matters; (6) implements fiscal controls; and (7) develops, coordinates, and monitors all functions related to the management of full-time equivalent (FTE) resources and makes recommendations on the allocation of FTEs/positions for NIH.

*Budget Reporting and Legislative Branch (NAM83, formerly HNAM83).* (1) Reviews, interprets, and assesses the impact of new and proposed legislation on the formulation and execution of the NIH budget; (2) collects and reports disease and other areas of special interest expenditure data and responds to requests from the public and Congress on funding of research in these areas; (3) tracks and analyzes

appropriations bills through House and Senate passage and conference; (4) manages the process of identifying reports and significant items requested by congressional appropriations committees and assigns responsibility for drafting responses; and (5) manages the production of materials for the appropriations hearings, including instructions and clearances for opening statements, production of questions and answers, and clearances for transcripts.

**Delegations of Authority Statement:** All delegations and redelegations of authority to officers and employees of NIH that were in effect immediately prior to the effective date of this establishment and are consistent with this amendment shall continue in effect, pending further redelegation.

Dated: February 11, 2003.

**Elias A. Zerhouni,**

*Director, National Institutes of Health.*

[FR Doc. 03-5212 Filed 3-5-03; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of Exclusive License: Human Monoclonal Antibody Biotherapeutics for the Treatment of Hepatitis C (HCV) Infections

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the invention embodied in United States Patent Application 60/250,561 filed December 1, 2000 and its foreign equivalents, entitled "Monoclonal Antibodies Specific for the E2 Glycoprotein of Hepatitis C Virus and Their Use in the Diagnosis, Treatment, and Prevention of HCV," to Virosys Pharmaceuticals, Inc., having a place of business in Redwood Shores, CA. The patent rights in this invention have been assigned to the United States of America.

**DATES:** Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before May 5, 2003 will be considered.

**ADDRESSES:** Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed

to: Susan Ano, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; E-mail: [anos@od.nih.gov](mailto:anos@od.nih.gov); Telephone: (301) 435-5515; Facsimile: (301) 402-0220.

**SUPPLEMENTARY INFORMATION:** This invention relates to human monoclonal antibodies that exhibit immunological binding affinity for the hepatitis C virus E2 glycoprotein and are cross-reactive against different hepatitis C virus (HCV) strains. These antibodies may be used in passive immunoprophylaxis for the prevention of hepatitis C virus infection and/or in passive immunotherapy for the treatment of hepatitis C.

The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The field of use may be limited to development of human monoclonal antibody biotherapeutics for the treatment of HCV infections.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: February 24, 2003.

**Steven M. Ferguson,**

*Acting Director, Division of Technology Development and Transfer, Office of Technology Transfer.*

[FR Doc. 03-5209 Filed 3-5-03; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of Exclusive License: Protein Biopharmaceuticals for Treatment of HIV Infections

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is

contemplating the grant of an exclusive license to practice the invention embodied in United States Patent Application 60/339,751 filed December 17, 2001 and its foreign equivalents, entitled "GP41 Inhibitor," to Virosys Pharmaceuticals, Inc., having a place of business in Redwood Shores, CA. The patent rights in this invention have been assigned to the United States of America.

**DATES:** Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before May 5, 2003 will be considered.

**ADDRESSES:** Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Susan Ano, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; E-mail: [anos@od.nih.gov](mailto:anos@od.nih.gov); Telephone: (301) 435-5515; Facsimile: (301) 402-0220.

**SUPPLEMENTARY INFORMATION:** This invention relates to a chimeric molecule, NCCG-gp41, in which the internal trimeric helical coiled-coil of the ectodomain of gp41 is fully exposed and stabilized by both fusion to a minimal ectodomain core of gp41 and by engineered intersubunit disulfide bonds. NCCG-gp41 inhibits HIV envelope mediated cell fusion at nanomolar concentrations with an IC50 of 16 nM. It is proposed that NCCG-gp41 targets the exposed C-terminal region of the gp41 ectodomain in its pre-hairpin intermediate state, thereby preventing the formation of the fusogenic form of the gp41 ectodomain that comprises a highly stable trimer of hairpins arranged in a six-helix bundle. NCCG-gp41 has potential as (a) An HIV therapeutic agent that inhibits cell entry; (b) as an AIDS vaccine and; (c) as a component of a high throughput screening assay for small molecule inhibitors of HIV envelope mediated cell fusion. Antibodies have been raised against NCCG-gp41 that inhibit HIV envelope mediated cell fusion.

The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The field of use may be limited to development of protein